EP1534336A4 - Anticorps se fixant de facon immunospecifique a des recepteurs trail - Google Patents

Anticorps se fixant de facon immunospecifique a des recepteurs trail

Info

Publication number
EP1534336A4
EP1534336A4 EP03788476A EP03788476A EP1534336A4 EP 1534336 A4 EP1534336 A4 EP 1534336A4 EP 03788476 A EP03788476 A EP 03788476A EP 03788476 A EP03788476 A EP 03788476A EP 1534336 A4 EP1534336 A4 EP 1534336A4
Authority
EP
European Patent Office
Prior art keywords
fixing
trail receptors
antibodies immunospecifically
immunospecifically
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03788476A
Other languages
German (de)
English (en)
Other versions
EP1534336A2 (fr
Inventor
Theodora Salcedo
Steven M Ruben
Craig A Rosen
Vivian A Albert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1534336A2 publication Critical patent/EP1534336A2/fr
Publication of EP1534336A4 publication Critical patent/EP1534336A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP03788476A 2002-08-15 2003-08-15 Anticorps se fixant de facon immunospecifique a des recepteurs trail Withdrawn EP1534336A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US40338202P 2002-08-15 2002-08-15
US403382P 2002-08-15
US42573002P 2002-11-13 2002-11-13
US425730P 2002-11-13
US46805003P 2003-05-06 2003-05-06
US468050P 2003-05-06
PCT/US2003/025457 WO2004016753A2 (fr) 2002-08-15 2003-08-15 Anticorps se fixant de facon immunospecifique a des recepteurs trail

Publications (2)

Publication Number Publication Date
EP1534336A2 EP1534336A2 (fr) 2005-06-01
EP1534336A4 true EP1534336A4 (fr) 2005-12-14

Family

ID=31892094

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03788476A Withdrawn EP1534336A4 (fr) 2002-08-15 2003-08-15 Anticorps se fixant de facon immunospecifique a des recepteurs trail

Country Status (4)

Country Link
EP (1) EP1534336A4 (fr)
AU (1) AU2003259835A1 (fr)
CA (1) CA2494372C (fr)
WO (1) WO2004016753A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
WO2005046732A2 (fr) * 2003-11-04 2005-05-26 THE UNITED SATES OF AMERICA as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES, NIH Methodes et compositions d'inhibition de la replication du vih-1
MXPA06006683A (es) * 2003-12-11 2006-08-11 Schering Ag Conjugado radiosensibilizador destinado a mejorar la eficacia de drogas radiorotuladas.
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
PE20140196A1 (es) 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
DK2257301T3 (da) 2008-03-03 2014-04-28 Univ Miami Immunterapi baseret på allogene cancerceller.
WO2013171287A1 (fr) * 2012-05-16 2013-11-21 Boehringer Ingelheim International Gmbh Combinaison d'anticorps anti-cd37 avec ice (ifosmamide, carboplatine, etoposide)
ES2812208T3 (es) 2013-03-14 2021-03-16 Bristol Myers Squibb Co Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso
BR112019001398A2 (pt) 2016-07-29 2019-05-07 Janssen Pharmaceutica Nv métodos para tratamento de câncer de próstata

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037684A1 (fr) * 1998-01-26 1999-07-29 Genentech, Inc. Anticorps du recepteur 4 de la mort cellulaire (dr4) et leurs utilisations
WO2002009755A2 (fr) * 2000-07-27 2002-02-07 Genentech, Inc. Synergisme de l'agoniste du recepteur de l'apo-2l et du cpt-11

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03010747A (es) * 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037684A1 (fr) * 1998-01-26 1999-07-29 Genentech, Inc. Anticorps du recepteur 4 de la mort cellulaire (dr4) et leurs utilisations
WO2002009755A2 (fr) * 2000-07-27 2002-02-07 Genentech, Inc. Synergisme de l'agoniste du recepteur de l'apo-2l et du cpt-11

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CHUNTHARAPAI A ET AL: "Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 APR 2001, vol. 166, no. 8, 15 April 2001 (2001-04-15), pages 4891 - 4898, XP002336508, ISSN: 0022-1767 *
DEJOSEZ M ET AL: "Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan", CELL DEATH AND DIFFERENTIATION, vol. 7, no. 11, November 2000 (2000-11-01), pages 1127 - 1136, XP002336507, ISSN: 1350-9047 *
DILLMAN ROBERT O: "Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY. 15 AUG 2002, vol. 20, no. 16, 15 August 2002 (2002-08-15), pages 3545 - 3557, XP009050751, ISSN: 0732-183X *
FULDA SIMONE ET AL: "Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo", NATURE MEDICINE, vol. 8, no. 8, August 2002 (2002-08-01), published online 15.07.2002, pages 808 - 815, XP002336506, ISSN: 1078-8956 *
GLINIAK B ET AL: "Enhanced therapeutic efficacy of TRAIL/Apo2L in combination with CPT-11 in the treatment of human tumor xenografts", PROCEEDINGS OF THE 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. SAN FRANCISCO, CA, APRIL 1 - 5, 2000, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, PA : AACR, US, vol. VOL. 41, 1 April 2000 (2000-04-01), pages 70, XP002207071 *
GLINIAK B ET AL: "TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND'S ANTITUMORACITVITY IN VIVO IS ENHANCED BY THE CHEMOTHERAPEUTIC AGENT CPT-11", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 24, 15 December 1999 (1999-12-15), pages 6153 - 6158, XP000941885, ISSN: 0008-5472 *
INOUE H ET AL: "HISTONE DEACETYLASE INHIBITORS SENSITIZE HUMAN COLONIC ADENOCARCINOMA CELL LINES TO TNF-RELATED APOPTOSIS INDUCING LIGAND-MEDIATED APOPTOSIS", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, SPANDIDOS, ATHENS, GR, vol. 9, no. 5, May 2002 (2002-05-01), pages 521 - 525, XP009007225, ISSN: 1107-3756 *
MITSIADES CONSTANTINE S ET AL: "TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: Therapeutic applications", BLOOD, vol. 98, no. 3, 1 August 2001 (2001-08-01), pages 795 - 804, XP002336504, ISSN: 0006-4971 *
NIMMANAPALLI R ET AL: "Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. FEB 2001, vol. 7, no. 2, February 2001 (2001-02-01), pages 350 - 357, XP002336505, ISSN: 1078-0432 *
ROEHN TILL A ET AL: "CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release", ONCOGENE, vol. 20, no. 31, 12 July 2001 (2001-07-12), pages 4128 - 4137, XP002336509, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
AU2003259835A1 (en) 2004-03-03
AU2003259835A8 (en) 2004-03-03
CA2494372A1 (fr) 2004-02-26
WO2004016753A3 (fr) 2004-06-17
EP1534336A2 (fr) 2005-06-01
CA2494372C (fr) 2013-05-28
WO2004016753A2 (fr) 2004-02-26

Similar Documents

Publication Publication Date Title
EP1465925A4 (fr) Anticorps se liant de maniere immunospecifique a des recepteurs trail
EP1572874A4 (fr) Anticorps se liant de maniere immunospecifique a des recepteurs de trail
CY2022005I1 (el) Βελτιστοποιημενα αντισωματα που στοχευουν to cd19
PL372662A1 (pl) Przeciwciała wobec alfav beta6
EE200300509A (et) Antikehad VLA-1 vastu
EP1616881A4 (fr) Anticorps anti-mpl
EP1728801A4 (fr) Sous-type d' anticorps humanise contre un recepteur de l'interleukine-6
FR15C0048I1 (fr) Anticorps antagonistes de il-17
EP1861626A4 (fr) Ensemble d'ancrage pour piece de fixation
CY2012003I2 (el) Αντισωματα που συνδεονται ανοσοειδικως προς blys
EP1506286A4 (fr) Anticorps anti-igfr humain neutralisant
NO20052889D0 (no) Humane monoklonale antistoffer mot CD25
EP1542721A4 (fr) Anticorps "s" modifies
DE602004024690D1 (de) Strukturkniepolster
EP1534336A4 (fr) Anticorps se fixant de facon immunospecifique a des recepteurs trail
EP1675606A4 (fr) Peptides et composes se liant a des recepteurs de thrombopoietine
EP1476583A4 (fr) Fixation resistante a la calcification
EP1633316A4 (fr) Anticorps se liant de maniere immunospecifique aux recepteurs trail
EP1781339A4 (fr) Composes de la guanylyle cyclase c
EP1598368A4 (fr) Anticorps de neutralisation anti-pci
EP1826218A4 (fr) Anticorps anti-baff humain
EP1339426A4 (fr) Anticorps a liaison immunospecifique avec les recepteurs "trail"
DE60128347D1 (de) Befestigen von schalenbauteilen an rohrleitungen
EP1272205A4 (fr) Anticorps du facteur-2 de la sialoadhesine
EP1646401A4 (fr) Anticorps humains specifiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050314

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 16/28 B

Ipc: 7C 07K 16/00 B

Ipc: 7A 61K 39/395 A

A4 Supplementary search report drawn up and despatched

Effective date: 20051028

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061020